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utations in paraplegin, a putative mitochondrial
metallopeptidase of the AAA family, cause an
autosomal recessive form of hereditary spastic
paraplegia (HSP). Here, we analyze the function of paraplegin
at the cellular level and characterize the phenotypic defects
of HSP patients’ cells lacking this protein. We demonstrate
that paraplegin coassembles with a homologous protein,
AFG3L2, in the mitochondrial inner membrane. These two
proteins form a high molecular mass complex, which we
show to be aberrant in HSP ﬁbroblasts. The loss of this
M
 
complex causes a reduced complex I activity in mitochondria
and an increased sensitivity to oxidant stress, which can
both be rescued by exogenous expression of wild-type
paraplegin. Furthermore, complementation studies in yeast
demonstrate functional conservation of the human para-
plegin–AFG3L2 complex with the yeast m-AAA protease
and assign proteolytic activity to this structure. These results
shed new light on the molecular pathogenesis of HSP and
functionally link AFG3L2 to this neurodegenerative disease.
 
Introduction
 
Both clinical and genetic heterogeneity apply to hereditary
spastic paraplegia (HSP), a disabling disorder affecting 1 in
10,000 people in the Western world (Polo et al., 1993). The
main phenotypic trait common to all forms of spastic para-
plegia is a progressive lower limb weakness, spasticity, and
decreased vibratory sense. Complicated forms show addi-
tional neurological signs such as retinopathy, optic neuro-
pathies, ataxia, dementia, and mental retardation (Harding,
1983). Neuropathological studies on pure HSP patients de-
scribe specific alterations of the cortical spinal tract due to
axonal degeneration of motor and sensory neurons without
cell body loss (Schwarz and Liu, 1956).
A more precise classification of HSP forms originates from
the inheritance pattern, which may be autosomal dominant,
autosomal recessive, or X-linked recessive. 20 different loci
have been associated with diverse forms of HSP (Crosby
and Proukakis, 2002; Reid, 2003); however, causative muta-
tions have been found in eight genes only. The most recent
gene associated with HSP is the neuronal specific kinesin
(KIF5A) gene 
 
SPG10
 
, a member of the kinesin superfamily
of molecular motors that transport cargoes along microtubules
in an ATP-dependent manner. Mutations in the cell adhe-
sion module L1, L1CAM (
 
SPG1
 
), and in the proteolipid
protein 
 
SPG2
 
 cause X-linked forms of HSP characterized by
defects in the development of the corticospinal tract and in
axonal–glial interactions, respectively. Little is known about
the four known autosomal HSP genes encoding atlastin
(
 
SPG3A
 
), spartin (
 
SPG20
 
), spastin (
 
SPG4
 
), and paraplegin
(
 
SPG7
 
), whereas HSP60 is a well-characterized shock re-
sponse protein (
 
SPG13
 
). Atlastin is a novel GTPase that has
sequence homology to members of the dynamin family of
large GTPases, particularly guanylate binding protein-1
(Zhao et al., 2001). Spartin is responsible for Troyer Syndrome,
an autosomal recessive HSP, and is homologous to proteins
 
L. Atorino and L. Silvestri contributed equally to this work.
Address correspondence to Giorgio Casari, Human Molecular Genetics
Unit, Dibit-San Raffaele Scientific Institute, Via Olgettina 58, 20132
Milan, Italy. Tel.: 39-02-26433502. Fax: 39-02-26434767. email:
g.casari@hsr.it
Key words: spasticity; mitochondria; respiratory complex; neurodegener-
ation; AAA protease
 
Abbreviations used in this paper: BN-PAGE, blue native PAGE; HSP,
hereditary spastic paraplegia; ROS, reactive oxygen species. 
778 The Journal of Cell Biology 
 
|
 
 
 
Volume 163, Number 4, 2003
 
involved in endosomal morphology and protein trafficking
of late endosomal component (Patel et al., 2002). Both spas-
tin and paraplegin are AAA proteins, which are ATPases as-
sociated with different cellular activities (Casari et al., 1998;
Hazan et al., 1999; Ogura and Wilkinson, 2001). Members
of this superfamily of ATPases exert chaperone-like activities
and mediate assembly and disassembly of macromolecular
structures involved in different cellular processes. Although a
still unclear role at the nuclear level exists (Charvin et al.,
2003), spastin interacts with microtubules and seems to
modulate microtubule dynamics, which is an essential at-
tainment for maintenance of long axons (Errico et al.,
2002).
Apart from these mutant proteins that associate the HSP
pathogenetic cascade to intracellular and axonal trafficking,
another pathogenetic mechanism points to the mitochon-
drion. In fact, both paraplegin and HSP60 are nuclear-
encoded mitochondrial proteins (Casari and Rugarli, 2001;
Hansen et al., 2002).
Paraplegin is closely related to ATP-dependent metallo-
proteases (Langer, 2000). By database scanning, two addi-
tional mitochondrial AAA proteases that are highly homolo-
gous to paraplegin have been identified, namely AFG3L2
and YME1L1 (Banfi et al., 1999; Coppola et al., 2000).
Yeast orthologues of these proteins are membrane-bound
peptidases, which ensure the quality control of mitochon-
drial inner membrane proteins (Leonhard et al., 1996).
Here, we analyze the function of paraplegin and its ho-
mologous protein, AFG3L2. They assemble in the mito-
chondrial inner membrane into a high molecular mass com-
plex, which is aberrant in HSP patients. Impaired complex
formation in HSP cells causes a decreased activity of respira-
tory complex I and increases the sensitivity to oxidative
stress. Heterologous expression of paraplegin and AFG3L2
in yeast cells and complementation studies establish the
complex as a proteolytically active structure involved in
maintenance of respiratory competence. Together, these
findings provide novel insights into the pathogenic mecha-
nism of neurodegeneration in HSP patients.
 
Results
 
Paraplegin and AFG3L2 assemble in the inner 
mitochondrial membrane into a high molecular 
mass complex, which is aberrant in HSP patients
 
Paraplegin is homologous to mitochondrial AAA metal-
loproteases that have been exclusively studied in fungi.
Two additional human members of the AAA metalloprote-
ase family, AFG3L2 and YME1L1, localize to mitochon-
dria (Banfi et al., 1999; Coppola et al., 2000). Although
YME1L1 is orthologous to the yeast protein Yme1p and
forms a homooligomeric structure able to rescue the 
 
 
 
y
 
me1
 
mutant yeast phenotype (Shah et al., 2000), the function of
paraplegin and AFG3L2 is not known.
The presence of two hydrophobic regions, which have the
characteristics of transmembrane domains (Casari et al.,
1998; Banfi et al., 1999), suggests that both paraplegin and
AFG3L2 are integral membrane proteins. To test this pre-
diction, we determined their submitochondrial localization.
Upon selective disruption of the mitochondrial outer mem-
brane by digitonin, both proteins are found exclusively in
the mitoplast fraction (Fig. 1 A, lane 1) as well as in HSP60,
which is a matrix marker (Fig. 1 A, lane 1). We also moni-
tored the presence of porin, as an outer membrane marker,
and cytochrome 
 
c
 
, as outer membrane and intermembrane
fractional markers, respectively. Porin, which resides on the
Figure 1. Submitochondrial localization and structural 
organization of the paraplegin–AFG3L2 complex. 
(A) Submitochondrial localization of paraplegin and 
AFG3L2 in human primary fibroblasts. Disruption of 
the mitochondrial outer membrane by digitonin: pellet/
mitoplast (lane 1) and supernatant fraction (lane 2); 
alkaline treatment of mitoplasts, isolating integral mem-
brane proteins (lane 3) and soluble/peripheral membrane 
proteins (lane 4). (B) Coimmunoprecipitation of paraple-
gin and AFG3L2. HEK293 mitochondrial lysate was 
immunoprecipitated with AFG3L2 antibody (lane 1) and 
paraplegin antibody (lane 3). Precipitates were analyzed 
by SDS-PAGE and immunostained using paraplegin 
(lane 1) or AFG3L2 (lane 3) antibodies. Corresponding 
preimmune sera were used as controls for the specificity 
of the coimmunoprecipitation (lanes 2 and 4). (C) Gel 
filtration analysis of mitochondrial extracts from HEK293. 
Isolated mitochondria are solubilized and fractionated 
by Superose 6-gel chromatography. Fractions are ana-
lyzed by SDS-PAGE and immunostained by antibodies 
recognizing paraplegin or AFG3L2 (fractions are from 
two gels: top, fractions 18 and 19, and 20–33; bottom, 
fractions 18–26 and 27–33) . The peaks of elution for 
various proteins of known molecular mass are indicated 
by lines (900 kD, ferritin dimer; 450 kD, ferritin mono-
mer; 232 kD, catalase). (D) Gel filtration analysis of 
mitochondrial extracts from control and HSP fibroblasts. 
Fractions are analyzed by SDS-PAGE and immuno-
stained by AFG3L2 antibody (fractions 18–26 and 27–33 
are from two gels). 
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outer membrane, but takes connections to the inner mem-
brane, was found either in the outer membrane–intermem-
brane fraction (Fig. 1 A, lane 2) or in the mitoplast fraction
as expected (Fig. 1 A, lane 1). Cytochrome 
 
c
 
 appears in the
outer membrane/intermembrane fraction (Fig. 1 A, lane 2).
Isolated mitoplasts were subjected to alkaline extraction
and divided into supernatant (containing matrix and periph-
eral membrane proteins) and membrane fractions (contain-
ing integral proteins of the inner membrane) by ultracentrif-
ugation. Paraplegin and AFG3L2 were recovered from the
membrane fraction, indicating that both are integral proteins
of the mitochondrial inner membrane (Fig. 1 A, lane 3).
To explore a potential physical interaction between para-
plegin and AFG3L2, we performed coimmunoprecipitation
studies in HEK293. Mitochondria were solubilized and sup-
plemented with either AFG3L2 or paraplegin antibodies.
Immunoblotting of the precipitates revealed that paraplegin
was isolated with AFG3L2 antibody and that, accordingly,
AFG3L2 coprecipitated with paraplegin antibody (Fig. 1 B,
lanes 1 and 3). Preimmune sera failed to precipitate any pro-
tein. We conclude from these experiments that paraplegin
assembles with AFG3L2.
To substantiate this conclusion, we performed gel filtra-
tion experiments. Mitochondria isolated from HEK293 cells
or from primary human control fibroblasts were solubilized
and fractionated. Eluate fractions were analyzed by immu-
noblotting using AFG3L2 and paraplegin antibodies. Both
proteins, which show a similar molecular mass of 
 
 
 
80 kD,
eluted in a rather broad peak from the column with fractions
corresponding to a molecular mass of 
 
 
 
800–900 kD (Fig.
1, C and D). Notably, the elution pattern of AFG3L2 was
altered in mitochondria from primary fibroblasts of HSP pa-
tients lacking paraplegin (see Materials and methods, Cell
cultures). In fact, AFG3L2 was present in a complex with a
reduced native molecular mass of 
 
 
 
250 kD (Fig. 1 D).
These data are in agreement with the complex formation
of paraplegin and AFG3L2, and they show that the paraple-
gin–AFG3L2 complex is aberrant in HSP cells lacking para-
plegin. The latter also suggests the inability of AFG3L2 to
homopolymerize or to assemble with other proteins to form
the 900-kD complex.
 
HSP cells show increased susceptibility to reactive 
oxygen species (ROS)
 
Because mitochondria are sensitive targets for ROS, we ex-
amined the sensitivity of HSP patients’ cells towards hydro-
gen peroxide (H
 
2
 
O
 
2
 
) challenge (1 h after 100 
 
 
 
M H
 
2
 
O
 
2
 
treatment). To assess the activity of mitochondria, the mem-
brane potential was monitored by staining control and HSP
fibroblasts with the potentiometric probes rhodamine 123
and JC-1.
Upon rhodamine staining, mitochondria in HSP fibro-
blasts subjected to ROS challenge displayed an increased
punctuate and diffuse pattern when compared with control
cells (Fig. 2 A). By using JC-1, the hyperpolarized orange-
staining mitochondria of HSP cells shift to greenish upon
H
 
2
 
O
 
2 
 
treatment faster than mitochondria of control cells
(Fig. 2 B). These results point to an increased sensitivity of
HSP fibroblasts towards oxidative damage, which is accom-
panied by depolarization of mitochondria.
The increased sensitivity towards ROS of HSP mitochon-
dria lacking the paraplegin–AFG3L2 complex was con-
firmed by measurements of mitochondrial ATP synthesis
(Fig. 3 A). ATP synthesis after H
 
2
 
O
 
2 
 
challenge (at 400 
 
 
 
M
for 4 h) was remarkably reduced in HSP fibroblasts com-
pared with controls (from 27.7 
 
 
 
 4 nmol ATP/mg protein
in untreated cells to 4.9 
 
 
 
 2.8 nmol ATP/mg protein in
H
 
2
 
O
 
2 
 
-treated cells; P 
 
 
 
 0.0005).
Cell vitality ascertained by MTT reduction assay con-
firmed the dose-dependent vulnerability of HSP cells to
ROS (upon exposure to 50 
 
 
 
M H
 
2
 
O
 
2 
 
for 8 h, 35.1 
 
 
 
 4.9%
HSP cells vs. 79.7 
 
 
 
 2.5% controls; at 200 
 
 
 
M, 30.0 
 
 
 
2.6% vs. 67.0 
 
 
 
 6.2%, P 
 
 
 
 0.000001; at 400 
 
 
 
M, 16.3 
 
 
 
4.7% vs. 52.3 
 
 
 
 7.7%, P 
 
 
 
 0.004; Fig 3 B). Catalase ad-
ministration showed a protective action both in HSP and
control cells exposed to H
 
2
 
O
 
2
 
 (unpublished data).
To examine whether the increased sensitivity of HSP fi-
broblasts towards oxidative stress is directly caused by a lack
of paraplegin, we set up paraplegin cDNA transfection ex-
periments. HSP and control cells were transfected with con-
structs harboring the full-length paraplegin cDNA or the
empty vector, and then were exposed to different concentra-
tions of H
 
2
 
O
 
2
 
. Cell damage was evaluated by assessing the
MTT metabolism (Fig. 3 C). The increased sensitivity of
HSP cells to oxidative stress was almost completely reversed
Figure 2. Mitochondrial depolarization of cells subjected to 
oxidative stress. Control and HSP fibroblasts are visualized by 
Rh123 (A) and JC-1 (B) staining.  
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to control values by exogenous expression of wild-type para-
plegin. Trypan blue exclusion assays revealed identical re-
sults (unpublished data). Together, these results demon-
strate an increased susceptibility to ROS of HSP patients’
fibroblasts lacking paraplegin, which can be reversed by
transfecting cells with paraplegin.
 
Impaired respiratory complex I activity 
in HSP fibroblasts
 
The decrease of ATP levels and mitochondrial transmem-
brane potential, together with the increased vulnerability of
HSP cells under oxidative stress, prompted us to explore
specific impairments of mitochondrial respiratory chain
complexes in HSP fibroblasts under standard growth condi-
tions. When compared with control cells, the growth rate of
HSP cells was strongly reduced in galactose medium (Fig. 4
A). This is characteristic of cells with defective mitochon-
drial metabolism (Robinson et al., 1992) and, therefore, in-
dicates an impaired respiratory activity in HSP cells even in
the absence of an induced oxidative stress.
To dissect the contribution of the different respiratory
chain complexes to mitochondrial ATP synthesis, we quan-
tified ATP production in permeabilized cells in the presence
of different substrates and inhibitors of respiratory com-
plexes. The basal activity of the respiratory chain in control
and HSP cells is similar (Fig. 4 B, group 1). By providing
pyruvate/malate or glutamate/malate (Fig. 4 B, groups 2 and
3), we stimulated ATP synthesis that is dependent on com-
plexes I, II, III, IV, and V. Using a complex I inhibitor, ro-
tenone, and succinate, we measured ATP production that is
dependent on complexes II, III, IV, and V (Fig. 4 B, group
4). Finally, incubating cells with antimycin A, an inhibitor
of complex III, and TMPD/ascorbate, we evaluated the ATP
level due to the activity of complexes IV and V (Fig. 4 B,
group 5). The ATP level measured in the presence of succi-
nate and ascorbate was the same in HSP and control cells,
suggesting that the activity of complexes II, III, IV, and V
was comparable. In contrast, we detected a substantial re-
duction of ATP synthesis in HSP cells using pyruvate and
glutamate as substrates, which stimulate the activity of the
overall respiratory chain complexes (i.e., complexes I, II, III,
IV, and V). These results correlate the observed reduction of
ATP synthesis with an impairment of complex I activity in
HSP cells. Similar experiments using isolated mitochondria
also revealed a significant decrease of complex I activity in
the absence of paraplegin (unpublished data).
Figure 3. Hydrogen peroxide challenge and phenotype rescue. 
(A) ATP depletion after oxidative stress. Data represent means of 
six independent experiments. (B) MTT reduction assay, data are 
expressed as percentage between the absorbance (570 nm) of 
treated and untreated cells; values, in triplicates, represent means 
of four independent experiments. (C) HSP and control cells trans-
fections by paraplegin expressing vector pSPG7. Data, in triplicates, 
are indicated as mean of three independent experiments. 
*, P   0.0005; **, P   0.000001. Bars represent  SEM.
Figure 4. Complex I deficiency in HSP fibroblasts. (A) Ratio of cell 
viability measured in galactose or glucose media; data, two replicates, 
represent means of three independent experiments. (B) ATP synthesis 
rates in permeabilized fibroblasts. 1, no substrate (basal activity); 2, 
pyruvate and L-malate (complexes I, II, III, IV, and V); 3, glutamate 
and L-malate (complexes I, II, III, IV, and V); 4, rotenone and succinate 
(complexes II, III, IV, and V); 5, antimycin, ascorbate, and TMPD 
(complexes IV and V). *, P   0.05; **, P   0.001; ***, P   0.0001. 
Bars represent  SEM. 
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To confirm this data, we used blue native PAGE (BN-
PAGE) to isolate enzymatically active membrane proteins
from mitochondria. In agreement with previous estimates
(Schagger et al., 1994; Klement et al., 1995), complex I of
both HSP and control cells exhibited a molecular mass of
 
 
 
750 kD (Fig. 5 A). By combining BN-PAGE with an in
situ activity staining reaction that specifically detects enzyme
activity of complex I, we confirmed a decrease in complex I
activity in HSP cells (Fig. 5 B, HSP) when compared with
control fibroblasts (Fig. 5 B, control). Transfection of HSP
cells with paraplegin partially recovered the activity of com-
plex I (Fig. 5 C, HSP/p
 
SPG7
 
), pointing to a direct role of
paraplegin in the regulation of this respiratory complex. 
The reduced activity of complex I in HSP fibroblasts
could reflect either a reduced specific activity of the enzy-
matic complex or a smaller number of complex I units per
mitochondrion. To distinguish between these possibilities,
we performed BN-PAGE followed by immunoblotting with
an antibody directed against the 39-kD subunit of complex
I. This experiment revealed a decreased amount of the as-
sembled complex I in HSP cells (Fig. 5 D, HSP), which can
be rescued to a normal level upon transfection with paraple-
gin cDNA (Fig. 5 E, HSP/p
 
SPG7
 
). 
The reduced amount of complex I may have different
causes: a defective expression, or import of nuclear-
encoded mitochondrial preproteins, or an inefficient syn-
thesis of mitochondrially encoded proteins. We addressed
these points by examining the mitochondrial import of the
39-kD protein in mitochondria from HSP and control fi-
broblasts. After protein synthesis in a cell-free system in the
presence of [
 
35
 
S]methionine and incubation of the radiola-
beled protein with isolated mitochondria, the 39-kD pro-
tein accumulated at similar levels in HSP and control fi-
broblasts, suggesting that the protein import machinery is
not impaired in HSP cells (Fig. 6 A). Consistently, the
whole amount of the 39-kD protein, including both the
unassembled and the complex I–assembled fractions, was
comparable in HSP and control mitoplasts as visualized by
Western blot analysis (Fig. 6 B). The mitochondrially en-
coded protein synthesis was measured by metabolic label-
ing of control and HSP cells in the presence of an inhibitor
of cytoplasmic protein synthesis. Similar amounts of pro-
Figure 5. Blue native gel electrophoresis of mitochondrial 
complexes. (A) Coomassie brilliant blue staining of mitoplast 
preparations. (B) Complex I in situ activity staining by nitro blue 
tetrazolium reduction assay. (C) Rescue of complex I in situ activity 
in HSP cells after pSPG7 transfection. (D and E) Western blot analysis 
of complex I revealed by anti–39-kD antibody. Immunoblotting with 
HSP60 antibody was used to verify equal loading. Activity and 
protein amount of complex I were quantified by densitometric 
analysis. *, P   0.05; **, P   0.001. Bars represent  SEM.
Figure 6. Mitochondrial import and protein synthesis in HSP and 
control fibroblasts. (A) Mitochondrial protein import efficiency of 
the 39-kD protein in control and HSP mitochondria (p, precursor; 
m, mature). (B) Western blot analysis of the 39-kD protein in control 
and HSP mitoplasts. (C) Mitochondrial protein synthesis in control 
and HSP cells (CO1, cytochrome c oxidase subunit I; ND2, NADH 
dehydrogenase subunit 2; COIII, cytochrome c oxidase subunit III; 
COII, cytochrome c oxidase subunit II; A6, ATPase subunit 6; A8, 
ATPase subunit 8). 
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teins are synthesized under these conditions (Fig. 6 C), in-
dicating that the decreased activity of complex I is not due
to an impaired synthesis of mitochondrially encoded sub-
units. Therefore, we conclude from these experiments that
the paraplegin–AFG3L2 complex is required for the effi-
cient assembly of complex I.
Because the chaperone-like and the proteasic activities of
the yeast mitochondrial metalloprotease complex are both
essential for the respiratory competence (Arlt et al., 1998),
we tested whether the proteolytic domain of paraplegin is re-
sponsible for the complex I rescue obtained on paraplegin
mutant fibroblast. Therefore, we mutagenized the glutamic
acid residue in position 575, which is conserved in the yeast
and human metal binding site, and when changed to gluta-
mine (E575Q; Fig. 7 A), is known to neutralize the protea-
sic activity (Arlt et al., 1996). As shown in Fig. 7 B, by ex-
pressing the mutagenized construct p
 
SPG7
 
Q575
 
, we were able
to revert the reduced activity of complex I of HSP fibroblasts
in a comparable manner to the construct expressing wild-
type paraplegin. Again, in our system, the complex I activity
is directly correlated to the assembled complex I amount
(Fig. 7 C). Hence, the integrity of the proteolytic domain of
paraplegin is not indispensable for the correct assembly of
complex I. The same pattern of results was obtained when
we analyzed the sensitivity to ROS. The mutagenized con-
struct p
 
SPG7
 
Q575 
 
rescued the increased sensitivity to oxidant
stress of HSP cells comparably to the wild-type construct
(unpublished data).
 
Coexpression of paraplegin and AFG3L2 restores 
the respiratory competence of 
 
yta10yta12
 
 mutant 
yeast cells
 
Paraplegin shares high sequence identity with subunits of
the m-AAA protease in the yeast 
 
Saccharomyces cerevisiae
 
,
Yta10 (Afg3) and Yta12 (Rca1; Casari et al., 1998). To ex-
amine functional conservation, we performed a complemen-
tation analysis in yeast. Mitochondrial targeting of paraple-
gin and AFG3L2 in the heterologous organism was ensured
by replacing their putative mitochondrial targeting se-
quences (amino acid residues 1–58 and amino acid residues
1–35, respectively) with the sorting signal of Yta10 (amino
acid residues 1–63). The resulting hybrid proteins were ex-
pressed in yeast cells lacking Yta10, Yta12, or both. Expres-
sion and mitochondrial localization were confirmed by im-
munoblotting of cell extracts (unpublished data). Yeast cells
lacking the m-AAA protease are respiratory deficient and
cannot use nonfermentable carbon sources like glycerol
(Tauer et al., 1994; Tzagoloff et al., 1994; Arlt et al., 1998).
Expression of paraplegin or AFG3L2 did not restore the re-
spiratory competence of 
 
 
 
yta10
 
 
 
yta12
 
 cells (Fig. 8 A) nor
of 
 
 
 
yta10 
 
or 
 
 
 
yta12
 
 (unpublished data). However, the re-
spiratory deficiency of 
 
 
 
yta10
 
 
 
yta12
 
 cells was suppressed
upon coexpression of both paraplegin and AFG3L2 (Fig. 8
A). Thus, in agreement with the experiments in the human
system, paraplegin and AFG3L2 functionally interact in
yeast mitochondria. Complex formation of both proteins in
yeast was subsequently observed by coimmunoprecipitation
experiments (unpublished data) and BN-PAGE (Fig. 8 B),
confirming that paraplegin and AFG3L2 act in a cooperative
manner in a 900-kD complex, and, thereby, can substitute
for the m-AAA protease in yeast.
These results demonstrate functional conservation of the
human paraplegin–AFG3L2 complex and the yeast m-AAA
protease. They also provide first evidence for a proteolytic
activity of paraplegin and AFG3L2 because maintenance of
the respiratory competence of yeast cells requires proteolysis
by the m-AAA protease (Arlt et al., 1998).
To substantiate this conclusion, point mutations were
introduced into the predicted proteolytic center of both
paraplegin and AFG3L2. Glutamic acid residues 575 in
the consensus metal binding sites of both proteins were re-
placed by glutamine residues by site-directed mutagenesis
(Fig. 7 A). The mutant proteins (fused to the mitochon-
drial targeting sequence of Yta10) were expressed in
 
 
 
yta10
 
 
 
yta12 
 
cells, and the respiratory competence was
examined. In contrast to the wild-type forms, coexpression
of mutant paraplegin and AFG3L2 did not confer respira-
tory competence to  yta10 yta12 cells, demonstrating
that the integrity of their proteolytic center is required for
functional complementation (Fig. 8 C). We analyzed the
expression of both subunits in these cells by Western blot-
ting and verified their correct targeting to mitochondria by
cell fractionation (unpublished data). Notably, coexpres-
sion of either mutant paraplegin or mutant AFG3L2 with
the respective wild-type counterpart already impaired the
Figure 7. Integrity of the proteasic site of paraplegin is not essential 
for complex I rescue. (A) Partial sequence alignment of human and 
yeast metalloproteases surrounding the divalent metal binding site 
(boxed area); the glutamic acid residue, E, replaced by glutamine, 
Q, is indicated. (B) Rescue of complex I in situ activity in HSP cells 
after pSPG7 and pSPG7
Q575 transfection. (C) Western blot analysis 
of complex I revealed by anti–39-kD antibody. Immunoblotting 
with HSP60 antibody was used to verify equal loading. Activity and 
protein amount of complex I were quantified by densitometric analysis. 
**, P   0.001. Bars represent  SEM.Paraplegin in hereditary spastic paraplegia | Atorino et al. 783
respiratory competence (Fig. 8 C). Thus, in contrast to the
yeast m-AAA protease (Arlt et al., 1998), the catalytic ac-
tivity of both subunits of the human paraplegin–AFG3L2
complex is required for proteolytic activity.
Discussion
Mutations in paraplegin are known to cause neurodegenera-
tion in an autosomal recessive form of HSP that approxi-
mately accounts for the 12% of recessive cases (unpublished
data). However, the pathogenetic mechanism of this disor-
der, particularly the role of mitochondria, is presently not
understood.
Here, we have identified paraplegin and its interactor, the
homologous protein AFG3L2, as part of a high molecular
mass complex in the inner membrane of mitochondria.
They form a complex of about 900 kD, which is aberrant in
HSP patients’ cells lacking paraplegin, where a smaller com-
plex of 250 kD is present. Our data identify the paraplegin–
AFG3L2 complex as a functionally active structure whose
absence plays a key role in the establishment of a cellular
phenotype in HSP fibroblasts. We observed a remarkable re-
duction of complex I (NADH–ubiquinone oxidoreductase)
activity in HSP cells compared with control cells. Further-
more, blue native gels confirmed this result and showed that
the reduction of complex I activity is due to stoichiometric
limitation of the enzymatic complex.
Our results reveal the first functional role of the paraplegin–
AFG3L2 complex in the biogenesis of the respiratory chain.
The deficiency is apparently caused by neither an impaired
import of nuclear-encoded proteins nor an inefficient synthe-
sis of mitochondrially encoded subunits, suggesting a role for
the paraplegin–AFG3L2 complex in effectively assembling
complex I. This defect was restored upon transfection of HSP
patients’ cells with a paraplegin-expressing vector.
A complementation study in yeast revealed, for the first
time, the functional conservation of mitochondrial m-AAA
proteases between distantly related species such as human
and yeast. In yeast cells, inactivation of m-AAA protease by
deleting one or both Yta10 and Yta12 causes pleiotropic
phenotypes because maintenance of the respiratory compe-
tence requires proteolysis by the yeast m-AAA protease (Arlt
et al., 1998). The respiratory deficiency of  yta10 yta12
cells (Langer, 2000) was suppressed by coexpression of para-
plegin and AFG3L2, providing the first evidence for their
proteolytic activity. This result was substantiated by the ob-
servation that the integrity of the proteolytic center of both
paraplegin and AFG3L2 is required for functional comple-
mentation. Thus, the complementation experiments in yeast
unambiguously demonstrate the proteolytic activity of the
paraplegin–AFG3L2 complex.
We expressed the proteolytic site variant of paraplegin in
paraplegin-deficient fibroblasts, and observed both a rescue
of complex I activity and an increased resistance towards
oxidative stress. This is reminiscent of findings in the yeast
system where the expression of a proteolytic site variant of
one homologous subunit of the m-AAA protease restores
respiratory competence (Arlt et al., 1998). The control ex-
periment demonstrating the inability of the mutant para-
plegin–AFG3L2 complex (i.e., coexpression of proteolytic
site variants of both paraplegin and AFG3L2) to rescue the
described HSP phenotypes is not feasible in human cells
because AFG3L2-deficient fibroblasts are currently not
available. However, we envision the following scenario ex-
plaining these findings in the two systems. Maintenance of
respiration in yeast requires only very low specific activity
of the m-AAA protease; hence, a single proteolytic site mu-
tant of a yeast subunit is sufficient for complementation.
Although we see complementation of the yeast double mu-
tant by the human paraplegin–AFG3L2 complex, the res-
Figure 8. Complementation assays of 
 yta10 yta12 yeast cells with paraplegin–
AFG3L2 complex. (A) Suppression of the 
respiratory deficiency of  yta10 yta12 yeast 
cells by paraplegin and AFG3L2 coexpression. 
Fivefold serial dilutions of yeast cells were 
spotted onto YP plates containing either 2% 
glucose (left, YPD) or 3% glycerol (right, YPG). 
(B) Western blot analysis of paraplegin–AFG3L2 
complex on BN-PAGE: the human m-AAA 
protease has been revealed by c-Myc antibody, 
recognizing the AFG3L2 fusion protein; the 
same band was observed in an identical blot 
decorated by HA antibody, recognizing the 
paraplegin fusion protein (not depicted). 
(C) Proteolytic activity of paraplegin and 
AFG3L2 is required for respiratory competence 
of  yta10 yta12 cells; yeast cells harboring a 
proteolytic site mutation in paraplegin, AFG3L2, 
or both were cultured and spotted on YP plates 
containing 3% glycerol.784 The Journal of Cell Biology | Volume 163, Number 4, 2003
cue of the respiratory competence is at the lower limit. In
fact, a further decrease of the specific activity of the pro-
tease complex (for instance by introducing a point muta-
tion into the proteolytic site of one subunit) abolishes com-
plementation, explaining the effect of a single proteolytic
site mutation of the human protease in yeast. However,
paraplegin–AFG3L2 complex is in the presence of the nat-
ural mitochondrial substrates in the autologous human sys-
tem. Lowering the proteolytic activity by introducing a
point mutation in the proteolytic site of paraplegin does
not completely inactivate the protease (as it happens in
yeast, when autologous elements are involved. This is due
to the presence of the wild-type copy of AFG3L2; there-
fore, we still observe complementation of an assembly de-
fect (as in yeast; Arlt et al., 1998).
In view of the observed functional conservation, we pro-
pose to term the paraplegin–AFG3L2 complex the human
m-AAA protease, which combines proteolytic and chaper-
one-like activities. The detected complex I deficiency in
HSP cells is very likely due to an inefficient folding process
in the absence of a physiological paraplegin–AFG3L2 com-
plex. Impaired complex I activity is frequently accompanied
by enhanced ROS production and lipid peroxidation (Barri-
entos and Moraes, 1999; Li et al., 2003). Indeed, an inti-
mate link between ROS and defects in the electron transport
function leading to a further increase in ROS production
plays an important role in the development and progression
of neurodegenerative diseases (Schapira et al., 1989; Wong
et al., 2002; Taylor et al., 2003). Therefore, we analyzed the
sensitivity of HSP patients’ cells towards oxidative stress,
and observed a significantly increased vulnerability of these
cells by ROS. This effect was restored, again, upon exoge-
nous expression of paraplegin. 
In HSP, complex I deficiency could directly contribute to
neurodegeneration via a free radical mechanism by direct
ROS production and by a decreased ATP synthesis leading
to energy failure. In particular, mitochondrial alterations
have been documented in neuronal aging (Beal, 1996), and
excessive production of ROS has been associated with differ-
ent forms of neurodegeneration including: Parkinson’s dis-
ease (Jenner and Olanow, 1996); Alzheimer’s disease (Behl,
1999); amyotrophic lateral sclerosis (Rosen et al., 1993;
Aguirre et al., 1998); Friedreich’s ataxia (Wong et al., 1999);
and, more recently, neurodegeneration related to prion in-
fection (Milhavet et al., 2000).
Neurons are particularly susceptible to oxidative stress due
to the high rate of oxidative metabolic activity, low level of
antioxidant enzymes, catalase and glutathione peroxidase,
extended axonal morphology prone to peripheral injury, and
impairment of the respiratory chain enzymes. In particular,
complex I is considered to be one of the most severely af-
fected by age-related increases in oxidative stress (Wong et
al., 2002). In synaptic mitochondria, this effect is even
worse (Davey et al., 1998). In addition, the effects of ROS
on mitochondrial respiratory activity limits the ability of
neuronal cells to respond appropriately to increase of ATP
demand (Sims et al., 2000; Mattson and Liu, 2002). These
findings, together with the evidence of a different complex I
distribution among types of neurons (Pettus et al., 2000),
may account for the selective vulnerability of a restricted
subset of neurons, and applies, in particular, to the retro-
grade axonopathy typical of HSP. 
Our findings shed new light on the molecular pathogene-
sis of HSP. We showed how paraplegin mutations suppress
the human m-AAA protease formation and generate com-
plex I deficiency in HSP cells, which may lead to additional
production of ROS causing oxidative stress in the particular
subset of neurons affected by HSP. Therefore, the initial
pathogenic mechanism is likely to stem from the combined
effects of misfolded peptide accumulation and the lack of
chaperone activity on complex I assembling. Specifically,
our results link this mitochondriopathy to the increas-
ing group of misfolding diseases such as Alzheimer’s dis-
ease, Parkinson’s disease, prion encephalopathies, and ex-
panded polyglutamine disease (Dobson, 1999; Temussi et
al., 2003). HSP commonly has a typical progressive course
and onset in the third or forth decade of life. This implies
that the phenotypic expression of this disease may involve
two factors, a predisposing mutation and an age-related fac-
tor that causes a decline in mitochondrial function, which
manifests the inherited defect.
Materials and methods
Reagents
Cell culture media and chemicals were purchased from Life Technologies
(Invitrogen) and Sigma-Aldrich, respectively.
Cell cultures
Primary fibroblasts were obtained from skin biopsies of two controls and
two HSP patients belonging to the original SPG7 family, homozygous for a
9.5-kb deletion in the SPG7 gene (patients no. IV-9 and IV-11; De Michele
et al., 1998). In addition, we obtained fibroblasts from a healthy hetero-
zygous individual belonging to the same family, which was used as an
internal control (patient no. IV-3). Primary fibroblasts and HEK293 were
cultured in   minimal essential medium supplemented with 2 mM L-gluta-
mine, 200 U/ml penicillin, 200 mg/ml streptomycin, and 20% FBS at 37 C
in 95% humidified air and 5% CO2.
Transfections
The paraplegin expression plasmid (pSPG7) was prepared by cloning the
full-length SPG7 cDNA (GenBank/EMBL/DDBJ accession no. Y16610) in a
modified pMT21 vector. The resulting recombinant plasmid was transiently
transfected by the calcium phosphate (Gualberto et al., 1998) and metafec-
tene (Biontex Laboratories) methods into cultured primary fibroblasts.
pSPG7 was mutagenized to obtain pSPG7
Q575 as described later for the
analogous yeast constructs (see Yeast expression constructs section).
Antibodies
To generate rabbit polyclonal antisera directed against paraplegin and
AFG3L2, we generated GST fusion proteins (pGEX2T; Amersham Bio-
sciences) with protein fragments spanning amino acids 243–844 of SPG7
gene product (GenBank/EMBL/DDBJ accession no. AAH07692) and amino
acids 413–828 of AFG3L2 gene product (GenBank/EMBL/DDBJ accession
no. Q9Y4W6). After expression in Escherichia coli, proteins were purified
according to standard procedures and used to immunize rabbits. Anti-
Hsp60 mAb was from StressGen Biotechnologies; anti–OxPhos complex I
39-kD subunit and mouse antiporin monoclonal antibodies from Molecu-
lar Probes were used. Anti–cytochrome c mAb was from Promega.
Isolation of mitochondria and mitoplasts
Mitochondria were isolated by differential centrifugation of HEK293 or fi-
broblast cell homogenates (Smith, 1967). In brief, cells were washed in
PBS, resuspended in an appropriate isotonic buffer (0.25 M sucrose, 5 mM
Tris-HCl, pH 7.5, and 0.1 mM PMSF) and homogenized using a glass tef-
lon homogenizer. Unbroken cells and nuclei were pelleted by centrifuga-
tion at 600 g for 15 min. Supernatants were centrifuged at 10,000 g for 25
min, and the mitochondrial pellet was washed once with the isotonic
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Mitoplasts were obtained by incubating mitochondria to a final protein
concentration of 1.0 mg/ml in PBS with 2.7 mg/ml digitonin for 20 min on
ice. The sample was centrifuged at 10,000 g for 10 min, and the final pel-
let (mitoplast fraction) was washed twice with PBS.
Isolation of integral proteins of the inner 
mitochondrial membrane
Isolation of integral proteins of the inner mitochondrial membrane was
performed by incubating mitoplasts in 100 mM Na2CO3 and 1 mM PMSF
(final solution pH 11.5) for 60 min on ice. Separation of the pellet (integral
protein of the inner membrane) and supernatant (soluble and matrix pro-
teins) was achieved by centrifugation at 70,000 g for 60 min at 4 C in a ul-
tracentrifuge (model Tl 100; Beckman Coulter; Pajic et al., 1994).
Coimmunoprecipitation
100  g of mitochondria isolated from HEK293 cells were resuspended at a
concentration of 500  g/ml in immunoprecipitation buffer (PBS containing
0.5% NP-40, 0.5 mM PMSF, 30  g/ml aprotinin, and 1 mM ATP) and in-
cubated with antiparaplegin, anti-AFG3L2 antisera, or preimmune sera for
2 h at 4 C in constant agitation. Subsequently, protein A–Sepharose was
added. Precipitates were used for Western blot analysis.
Gel filtration analysis
1 mg of isolated mitochondria was solubilized at 5 mg/ml with 0.25% NP-
40 in PBS supplemented with 1 mM ATP. Mitochondrial extracts were
centrifuged for 30 min at 109,000 g in an ultracentrifuge. Supernatants
were applied onto a Superose 6-gel filtration column (Amersham Bio-
sciences) and chromatographed at a flow rate of 0.5 ml/min in solubiliza-
tion buffer. Calibration standards included ferritin (monomer: 450 kD;
dimer: 900 kD), catalase (232 kD), and myoglobin (17.5 kD). 0.5-ml frac-
tions were collected; TCA was precipitated and analyzed by SDS-PAGE
and Western blotting using AFG3L2- or paraplegin-specific antisera.
Oxidant challenge
Primary fibroblasts were plated at a density of 10
5 cells/cm
2 and allowed to
grow for 24 h before treatments. Cultures showing  98% viable cells were
treated under different H2O2 concentrations (0–400  M); in separated exper-
iments, cells were incubated with 400  M H2O2 and 400 U/ml catalase. Af-
ter 8 h of incubation, cell vitality was evaluated by trypan blue exclusion as-
say (Reese and Byard, 1981) or MTT reduction assay (Liu et al., 1997).
To evaluate the effect of H2O2 on the ATP level, after 5 h of incubation,
cells were lysed with the ATP lysis buffer (see Luminometric assay of ATP
section), and ATP was measured using the Luciferin-Luciferase method
(Ronner et al., 1999).
Mitochondrial membrane potential
Primary fibroblasts were stained with 0.5  M JC-1 (Molecular Probes; Diaz
et al., 1999) and with 5  M Rh123 (Johnson et al., 1980) in culture me-
dium at 37 C for 30 min. JC-1 produces two emissions depending on the
mitochondrial membrane potential (orange signal, high polarized mito-
chondria; green signal, low polarized mitochondria; green cytoplasmic
signal, depolarized mitochondria), whereas active mitochondria stained
with Rh123 appear yellow-green. The picture acquisition system was
Eclipse E600 with a digital camera (model DXM1200; Nikon).
Respiratory chain activity
Tests for respiratory chain defects were essentially performed as described
by Robinson (1996). In brief, digitonin-permeabilized cells or isolated mi-
tochondria were incubated at 37 C for 30 min in a respiratory buffer (0.25
M sucrose, 20 mM MOPS, 1 mM EDTA, 5 mM inorganic phosphate, 0.1%
BSA fatty acid free, and 1 mM ADP, pH 7.4) containing specific substrates
and inhibitors of the respiratory chain complexes. By providing pyruvate/
malate (5 mM and 1 mM, respectively) and glutamate/malate (5 mM and 1
mM, respectively), we stimulated ATP synthesis dependent on complexes
I, II, III, IV, and V. Using a complex I inhibitor, 1  M rotenone, and 10 mM
succinate, we measured ATP production that is dependent on complexes
II, III, IV, and V. Finally, incubating cells with 20  g/ml antimycin A, an in-
hibitor of complex III, and TMPD/ascorbate (0.1 mM and 2 mM, respec-
tively), we evaluated the ATP level due to the activity of complexes IV and
V. ATP production was measured by luminometric assay. A t test was ap-
plied for significance calculation.
Luminometric assay of ATP
ATP concentration was determined with the Luciferin-Luciferase method
as described previously (Ronner et al., 1999); in brief, the assay solution
was prepared as follows: 250 mM glycilglycine, 2 mM EGTA, 2 mM
MgCl2, 0.4 g/liter BSA fatty acid free, 7.5 mM DTT, 15  M luciferin, and
10  g/ml luciferase. Cells were lysed with the ATP lysis buffer (0.2 M
NaOH and 0.5 mM EDTA), and an aliquot of the obtained extract was di-
luted with the ATP dilution buffer (0.1 M NaOH and 0.5 mM EDTA). In the
luminometer, 20  l of this mixture was added to 100  l of the assay solu-
tion, and the ATP content was measured. Data were expressed as nano-
moles of ATP per milligram of protein (Bradford, 1976).
BN-PAGE and complex I in situ activity staining
Isolated mitoplasts were solubilized at a protein concentration of 5 mg/ml
by dodecyl maltoside (2% final concentration) and centrifuged, and super-
natants were loaded on a linear 5–13% gradient polyacrylamide gel. Gels
were stained with coomassie brilliant blue or transblotted on a nitrocellu-
lose membrane and immunodecorated with anti–39-kD antibody (Schag-
ger et al., 1994). Complex I in situ activity staining was performed by incu-
bation of the gel in 0.1 M Tris-HCl, 0.14 mM NADH, and 1 mg/ml nitro
blue tetrazolium, pH 7.4; the reaction was carried out at RT and stopped
after 30 min by 45% methanol and 10% acetic acid (Jung et al., 2000).
Band quantifications relative to in situ activity staining gels and Western
blots have been performed by densitometric analysis (densitometer, Epson
Twain Pro); a t test was used for significant calculation.
Import of 39-kD subunit of respiratory complex I in 
mitochondria isolated from control and HSP fibroblasts
Mitochondria from control and HSP fibroblasts were isolated as described
previously, and import assay was performed (Yano et al., 2000). Precursor
protein 39 kD was synthesized by in vitro transcription and translation in
the presence of [
35S]methionine (TNT-coupled retuculocyte lysate system;
Promega). The mitochondrial import assay was performed as follows: 660
 g of mitochondria was resuspended in 35  l of mannitol buffer (225 mM
mannitol, 25 mM sucrose, 10 mM Tris-HCl, pH 7.8, and 0.1 mM EDTA)
and incubated with 70  l of translate, 0.6  l of 180 mM malate, and 1.1  l
of 1 M pyruvate. After 15, 45, and 135 min, 20- l aliquots were removed,
transferred to a fresh tube, incubated with trypsin, and centrifuged at
13,000 g for 5 min at 4 C. Pellets were washed once with mannitol buffer
and resuspended in sample buffer for electrophoretic analysis in 12% SDS-
PAGE. The imported protein was analyzed by fluorography.
Mitochondrial protein synthesis analysis
Primary fibroblasts were labeled with [
35S]methionine (1,000 Ci/mmol and
100  Ci/ml) for 2 h in presence of 200  g/ml cycloeximide as described
previously (Chomyn, 1996). After labeling, the cells were washed and di-
rectly lysed in a sample buffer containing 62.5 mM Tris/HCl, pH 6.8, 2%
(vol/vol) 2-mercaptoethanol, 1% (wt/vol) SDS, and 0.01% bromophenol
blue. The mitochondrial translation products were analyzed by 15% SDS-
PAGE and autoradiography.
Yeast expression constructs
Mature forms of paraplegin and AFG3L2 were fused to a mitochondrial
leader peptide to ensure efficient mitochondrial import in the yeast.
Precisely, the mature paraplegin (amino acids 59–795; GenBank/EMBL/
DDBJ accession no. AAH07692) and AFG3L2 (amino acids 36–798; Gen-
Bank/EMBL/DDJB accession no. Q9Y4W6) were tagged with the HA and
c-Myc epitopes, respectively, and fused to the mitochondrial targeting se-
quence of YTA10 (amino acids 1–63; GenBank/EMBL/DDJB accession no.
S46611). The constructs were cloned into the vectors YcpLac111 (paraple-
gin) and pRS316 (AFG3L2) under the ADH1 promoter. Paraplegin and
AFG3L2 were mutagenized in the yeast expression constructs using a site-
directed mutagenesis kit (model QuickChange XL; Stratagene) and the fol-
lowing oligonucleotides: 5’-GTG GTT GCG TTT CAT CAG TCG GGC
CAC GCC-3’ (forward primer) and 5’-GGC GTG GCC CGA CTG ATG
AAA CGC AAC CAC-3’ (reverse primer) for paraplegin; 5’-CTG TGG CAT
ACC ACC AAG CAG GCC ATG CGG-3’ (forward primer) and 5’-CCG CAT
GGC CTG CTT GGT GGT ATG CCA CAG-3’ (reverse primer) for AFG3L2.
The codon GAA coding for glutamic acid residue 575 of paraplegin was
replaced by CAG coding for glutamine. In case of AFG3L2, glutamic acid
residue 575 was replaced by glutamine, mutating the respective codon
GAA to CAA. Mutagenesis was verified by DNA sequencing.
Yeast strains were transformed with the described vectors and cultivated
on synthetic medium supplemented with 2% glucose (YPD) or 3% glycerol
(YPG). To allow adaptation to respiratory conditions, cells grown on YPD
plates were shifted to glycerol-containing YP medium and incubated for 6 d
before spotting on YPG plates, as described previously (Arlt et al., 1996).
BN-PAGE and Western blot analysis on yeast mitochondria were per-
formed as described in BN-PAGE and complex I in situ activity staining;786 The Journal of Cell Biology | Volume 163, Number 4, 2003
human paraplegin–AFG3L2 complex was revealed by the anti–c-Myc
(9E10; 10  g/ml).
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